Key facts
- This page summarizes Michael M. Abecassis's Form 4 filing for PharmaCyte Biotech, Inc. (PMCB).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Dec 2025, 17:06.
Michael M. Abecassis - 25 Apr 2025 Form 4 Insider Report for PharmaCyte Biotech, Inc. (PMCB)
- Reporting relationship
- Director
- Issuer ticker
- PMCB
- Reported as of
- 25 Apr 2025
- Net transaction value
- -$17,212
- SEC form
- 4
- Accepted by SEC
- 12 Dec 2025, 17:06:55 UTC
- Prior SEC filing
- 17 Jul 2024
- Next SEC filing
- 02 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael M. Abecassis
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael M. Abecassis filed Form 4 for PharmaCyte Biotech, Inc. (PMCB) on 12 Dec 2025.
Change
- Previous filing in this sequence was filed on 17 Jul 2024.
- Current net transaction value: -$17,212.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001879281
Primary reporting owner
Abecassis Michael M
- Relationship
- Director
- Address
- C/O PHARMACYTE BIOTECH, INC., 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS
- Signature
- /s/ Michael M. Abecassis
- Signature date
- 12 Dec 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PMCB
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +37,500
- Change %
- +2250%
- Price
- $0.000000
- Shares after
- 39,167
- Date
- 12 Dec 2025
- Ownership
- Direct
PMCB
transaction
Common Stock
Tax liability
- Transaction value
- $17,212
- Shares
- -16,875
- Change %
- -43%
- Price
- $1.02
- Shares after
- 22,292
- Date
- 12 Dec 2025
- Ownership
- Direct
- Footnotes
- F1
PMCB
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 800
- Date
- 25 Apr 2025
- Ownership
- By Transplant Consulting LLC
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PMCB
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +63,233
- Change %
- Price
- $0.000000
- Shares after
- 63,233
- Date
- 25 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 63,233
- Exercise price
- $1.22
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction.
Footnote F2
The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Abecassis. This transaction is late due to an inadvertent administrative error and not any error of Mr. Abecassis.